Technology Innovation Group (TIG) is results-oriented and we measure our success in terms of tangible and quantifiable benefits. This includes such measures as amount of money raised, number of partnerships created, governmental policy and programmatic changes, and numbers of companies launched and technologies successfully commercialized.
Helped create three public-private partnerships that, since inception, have raised over $120 million in funding support from universities, government agencies, NGOs and private companies. These three PPPs have had significant economic impact on the regions/industries supported.
Raised multiple rounds of funding three start-up companies: TissueGen, ODC and Eliance Biotech. TIG principals served as initial CEOs in all three companies and led successful transitions in executive management for all companies.
Conducted national science and technology assessments for Jordan and South Africa, leading to approval of policy and programmatic recommendations and follow-up projects to implement solutions.
Commercialized promising technologies from medical research institutions through a spin-out company led by a TIG principal serving as initial CEO, and through obtaining orphan drug status from FDA and licensing the technology to a third party.